Dohlman Claes H, Cade Fabiano, Regatieri Caio V, Zhou Chengxin, Lei Fengyang, Crnej Alja, Harissi-Dagher Mona, Robert Marie-Claude, Papaliodis George N, Chen Dongfeng, Aquavella James V, Akpek Esen K, Aldave Anthony J, Sippel Kimberly C, DʼAmico Donald J, Dohlman Jan G, Fagerholm Per, Wang Liqiang, Shen Lucy Q, González-Andrades Miguel, Chodosh James, Kenyon Kenneth R, Foster C Stephen, Pineda Roberto, Melki Samir, Colby Kathryn A, Ciolino Joseph B, Vavvas Demetrios G, Kinoshita Shigeru, Dana Reza, Paschalis Eleftherios I
Cornea Service and Boston Keratoprosthesis Laboratory, Massachusetts Eye and Ear Infirmary and Schepens Eye Research Institute, Harvard Medical School, Boston, MA.
Cornea. 2018 Feb;37(2):248-251. doi: 10.1097/ICO.0000000000001438.
To propose a new treatment paradigm for chemical burns to the eye - in the acute and chronic phases.
Recent laboratory and clinical data on the biology and treatment of chemical burns are analyzed.
Corneal blindness from chemical burns can now be successfully treated with a keratoprosthesis, on immediate and intermediate bases. Long term outcomes, however, are hampered by early retinal damage causing glaucoma. New data suggest that rapid diffusion of inflammatory cytokines posteriorly (TNF-α, etc) can severely damage the ganglion cells. Prompt anti-TNF-α treatment is markedly neuroprotective. Long term profound reduction of the intraocular pressure is also vital.
A new regimen, in addition to standard treatment, for severe chemical burns is proposed. This involves tumor necrosis factor alpha (TNF-α) inhibition promptly after the accident (primarily for retinal neuroprotection), prophylactic maximal lowering of the intraocular pressure (starting immediately), and keratoprosthesis implantation in a later quiet state.
提出一种针对眼部化学烧伤急性期和慢性期的新治疗模式。
分析近期有关化学烧伤生物学及治疗的实验室和临床数据。
现在可以通过角膜移植术即时和中期成功治疗化学烧伤导致的角膜盲。然而,长期预后受到早期视网膜损伤导致青光眼的阻碍。新数据表明,炎症细胞因子(如肿瘤坏死因子-α等)向后快速扩散会严重损害神经节细胞。及时的抗肿瘤坏死因子-α治疗具有显著的神经保护作用。长期深度降低眼压也至关重要。
除标准治疗外,还提出了一种针对严重化学烧伤的新方案。这包括事故后立即抑制肿瘤坏死因子-α(主要用于视网膜神经保护)、预防性最大程度降低眼压(立即开始)以及在后期病情稳定时进行角膜移植术。